NO2023022I1 - cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate - Google Patents

cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate

Info

Publication number: NO2023022I1
Authority: NO; Norway
Prior art keywords: cobimetinib; acceptable salts; sovates; optionally; hemifumarate
Prior art date: 2005-10-07

Application number

NO2023022C

Other languages

English (en)

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-07

Filing date

2023-05-11

Publication date

2023-05-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37728416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2023022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2023-05-11 Application filed by Exelixis Inc filed Critical Exelixis Inc

2023-05-11 Publication of NO2023022I1 publication Critical patent/NO2023022I1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pyridine Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO2023022C 2005-10-07 2023-05-11 cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate NO2023022I1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72457805P	2005-10-07	2005-10-07
US80284006P	2006-05-23	2006-05-23

Publications (1)

Publication Number	Publication Date
NO2023022I1 true NO2023022I1 (no)	2023-05-11

Family

ID=37728416

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO20200035A NO347091B1 (no)	2005-10-07	2006-10-05	Forbindelser og farmasøytiske sammensetninger til behandling av proliferative sykdommer
NO20082088A NO344876B1 (no)	2005-10-07	2008-05-05	MEK inhibitorer og farmasøytiske sammensetninger inneholdende slike
NO2020031C NO2020031I1 (no)	2005-10-07	2020-09-04	kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
NO2023022C NO2023022I1 (no)	2005-10-07	2023-05-11	cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
NO20200035A NO347091B1 (no)	2005-10-07	2006-10-05	Forbindelser og farmasøytiske sammensetninger til behandling av proliferative sykdommer
NO20082088A NO344876B1 (no)	2005-10-07	2008-05-05	MEK inhibitorer og farmasøytiske sammensetninger inneholdende slike
NO2020031C NO2020031I1 (no)	2005-10-07	2020-09-04	kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat

Country Status (32)

Country	Link
US (9)	US7803839B2 (no)
EP (1)	EP1934174B1 (no)
JP (8)	JP5129143B2 (no)
KR (2)	KR20130058072A (no)
CN (5)	CN101365676B (no)
AT (1)	ATE504565T1 (no)
AU (1)	AU2006302415B2 (no)
BR (1)	BRPI0617165B1 (no)
CA (3)	CA2622755C (no)
CY (2)	CY1111670T1 (no)
DE (1)	DE602006021205D1 (no)
DK (1)	DK1934174T3 (no)
EA (3)	EA025871B9 (no)
ES (1)	ES2365070T3 (no)
FR (1)	FR16C0021I2 (no)
GE (1)	GEP20125456B (no)
HK (2)	HK1119698A1 (no)
HR (1)	HRP20110498T1 (no)
HU (1)	HUS1600021I1 (no)
IL (5)	IL189900A (no)
LT (1)	LTC1934174I2 (no)
LU (1)	LU93078I2 (no)
MY (1)	MY162174A (no)
NL (1)	NL300809I2 (no)
NO (4)	NO347091B1 (no)
NZ (1)	NZ567140A (no)
PL (1)	PL1934174T3 (no)
PT (1)	PT1934174E (no)
RS (1)	RS51782B (no)
SI (1)	SI1934174T1 (no)
WO (1)	WO2007044515A1 (no)
ZA (1)	ZA200802075B (no)

Families Citing this family (252)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005298932B2 (en) *	2004-10-20	2012-03-22	Merck Serono Sa	3-arylamino pyridine derivatives
NO347091B1 (no) *	2005-10-07	2023-05-15	Exelixis Inc	Forbindelser og farmasøytiske sammensetninger til behandling av proliferative sykdommer
GB0601962D0 (en)	2006-01-31	2006-03-15	Ucb Sa	Therapeutic agents
EP2056829B9 (en) *	2006-08-16	2012-09-26	Exelixis, Inc.	Using pi3k and mek modulators in treatments of cancer
CA2667961A1 (en)	2006-10-31	2008-05-08	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors
AU2007334402B2 (en) *	2006-12-14	2014-02-13	Exelixis, Inc.	Methods of using MEK inhibitors
WO2008124085A2 (en) *	2007-04-03	2008-10-16	Exelixis, Inc.	Methods of using combinations of mek and jak-2 inhibitors
WO2008139287A1 (en) *	2007-05-10	2008-11-20	Pfizer Limited	Azetidine derivatives and their use as prostaglandin e2 antagonists
WO2009012256A1 (en)	2007-07-16	2009-01-22	Genentech, Inc.	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
AR067544A1 (es)	2007-07-16	2009-10-14	Genentech Inc	Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos
GB0714384D0 (en)	2007-07-23	2007-09-05	Ucb Pharma Sa	theraputic agents
EP2240494B1 (en)	2008-01-21	2016-03-30	UCB Biopharma SPRL	Thieno-pyridine derivatives as mek inhibitors
CN104650230A (zh)	2008-01-31	2015-05-27	健泰科生物技术公司	抗cd79b抗体和免疫偶联物及使用方法
CN104888232B (zh)	2008-03-18	2019-05-10	健泰科生物技术公司	抗her2抗体-药物偶联物和化疗剂的组合，及使用方法
GB0811304D0 (en)	2008-06-19	2008-07-30	Ucb Pharma Sa	Therapeutic agents
WO2010003025A1 (en)	2008-07-01	2010-01-07	Genentech, Inc.	Bicyclic heterocycles as mek kinase inhibitors
AU2009266953A1 (en)	2008-07-01	2010-01-07	Genentech, Inc.	Isoindolone derivatives as MEK kinase inhibitors and methods of use
US9084781B2 (en)	2008-12-10	2015-07-21	Novartis Ag	MEK mutations conferring resistance to MEK inhibitors
AU2010224125B2 (en)	2009-03-12	2015-05-14	Genentech, Inc.	Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
SG175708A1 (en)	2009-05-27	2011-12-29	Genentech Inc	Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
KR20140034948A (ko)	2009-09-28	2014-03-20	에프. 호프만-라 로슈 아게	벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법
MY184074A (en)	2009-09-28	2021-03-17	Hoffmann La Roche	Benzoxazepin p13k inhibitors compounds and methods of use
CA2776944A1 (en) *	2009-10-12	2011-05-12	F. Hoffmann-La Roche Ag	Combinations of a pi3k inhibitor and a mek inhibitor
WO2011054828A1 (en) *	2009-11-04	2011-05-12	Novartis Ag	Heterocyclic sulfonamide derivatives useful as mek inhibitors
AR079256A1 (es)	2009-12-04	2012-01-04	Genentech Inc	Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
US9073927B2 (en)	2010-01-22	2015-07-07	Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii	Inhibitors of PI3 kinase
BR112012019635A2 (pt)	2010-02-22	2016-05-03	Hoffmann La Roche	compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
AU2011221227B2 (en)	2010-02-25	2015-07-09	Dana-Farber Cancer Institute, Inc.	BRAF mutations conferring resistance to BRAF inhibitors
KR20120139767A (ko)	2010-03-09	2012-12-27	더 브로드 인스티튜트, 인코퍼레이티드	1차 암 요법에 대한 저항성을 갖는 또는 발달시키는 환자에서 암을 진단 및 치료하는 방법
WO2011121317A1 (en)	2010-04-01	2011-10-06	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
KR101464060B1 (ko)	2010-04-07	2014-11-20	에프. 호프만-라 로슈 아게	피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
EA024730B1 (ru)	2010-04-15	2016-10-31	Медимьюн Лимитед	Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов
TWI503319B (zh)	2010-05-07	2015-10-11	Gilead Connecticut Inc	吡啶酮和氮雜吡啶酮之化合物及其使用方法
BR112013000867A2 (pt)	2010-07-14	2016-05-17	Hoffmann La Roche	composto de purina seletivos para delta p110 de pi3k e métodos de uso.
EP2598660B1 (en)	2010-07-26	2017-03-15	Biomatrica, INC.	Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en)	2010-07-26	2017-09-27	Biomatrica, INC.	Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
KR101837223B1 (ko)	2010-09-01	2018-03-09	질레드 코네티컷 인코포레이티드	피리디논/피라지논, 그의 제조 방법 및 사용 방법
KR101864908B1 (ko)	2010-09-01	2018-06-05	질레드 코네티컷 인코포레이티드	피리다지논, 그의 제조 방법 및 사용 방법
WO2012052745A1 (en)	2010-10-21	2012-04-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012068096A2 (en)	2010-11-15	2012-05-24	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
KR20140099556A (ko)	2010-12-16	2014-08-12	에프. 호프만-라 로슈 아게	트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
KR20130116358A (ko)	2011-02-09	2013-10-23	에프. 호프만-라 로슈 아게	Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
WO2012126901A1 (en)	2011-03-21	2012-09-27	F. Hoffmann-La Roche Ag	Benzoxazepin compounds selective for pi3k p110 delta and methods of use
CN102718750B (zh) *	2011-03-31	2015-03-11	中国人民解放军军事医学科学院毒物药物研究所	含吖啶环的氨基吡啶类衍生物及其用途
CA2844699C (en)	2011-04-01	2019-05-07	Genentech, Inc.	Combinations of akt inhibitor compounds and abiraterone, and methods of use
CN103841976A (zh)	2011-04-01	2014-06-04	基因泰克公司	Akt和mek抑制剂化合物的组合及其使用方法
PL2710018T3 (pl)	2011-05-19	2022-04-04	Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Związki makrocykliczne jako inhibitory kinaz białkowych
EP2524918A1 (en)	2011-05-19	2012-11-21	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyrazines derivates as kinase inhibitors
EP2714046A1 (en)	2011-06-03	2014-04-09	F.Hoffmann-La Roche Ag	Methods of treating mesothelioma with a pi3k inhibitor compound
JP6238459B2 (ja)	2011-08-01	2017-11-29	ジェネンテック，インコーポレイテッド	Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
WO2013024002A1 (en)	2011-08-12	2013-02-21	F. Hoffmann-La Roche Ag	PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
SG2014012579A (en)	2011-09-27	2014-04-28	Hoffmann La Roche	Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
BR112014009050B1 (pt)	2011-10-14	2022-06-21	Medimmune Limited	Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
AU2012328980A1 (en) *	2011-10-28	2014-04-24	Genentech, Inc.	Therapeutic combinations and methods of treating melanoma
UA111756C2 (uk)	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
JP5976826B2 (ja)	2011-11-03	2016-08-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｂｔｋ活性阻害剤としての８−フルオロフタラジン−１（２ｈ）−オン化合物
PE20141686A1 (es)	2011-11-03	2014-11-08	Hoffmann La Roche	Compuestos de piperazina alquilados como inhibidores de actividad btk
US8722676B2 (en)	2011-11-03	2014-05-13	Genentech, Inc.	Bicyclic piperazine compounds
EP2592103A1 (en)	2011-11-08	2013-05-15	Adriacell S.p.A.	Polymer aldehyde derivatives
CN104302669A (zh)	2011-11-23	2015-01-21	伊格尼卡生物治疗公司	抗cd98抗体及其使用方法
WO2013082511A1 (en)	2011-12-02	2013-06-06	Genentech, Inc.	Methods for overcoming tumor resistance to vegf antagonists
CN103204827B (zh)	2012-01-17	2014-12-03	上海科州药物研发有限公司	作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
US9897607B2 (en)	2012-02-01	2018-02-20	The Governors Of The University Of Alberta	Methods, kits, and systems for treatment of metastatic papillary thyroid cancer
WO2013169858A1 (en)	2012-05-08	2013-11-14	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
KR101689946B1 (ko)	2012-06-08	2016-12-26	에프. 호프만-라 로슈 아게	암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CA2871388A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	5-azaindazole compounds and methods of use
CN104797270A (zh)	2012-08-02	2015-07-22	基因泰克公司	抗etbr抗体和免疫偶联物
MX2015001399A (es)	2012-08-02	2015-09-07	Genentech Inc	Anticuerpos anti-etbr e inmunoconjugados.
AU2013302861A1 (en) *	2012-08-13	2015-03-05	The Rockefeller University	Treatment and diagnosis of melanoma
DK2884979T3 (da)	2012-08-17	2019-09-02	Hoffmann La Roche	Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
BR112015002493A8 (pt)	2012-08-30	2019-07-30	Hoffmann La Roche	composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, kit e uso de um composto”
SG11201502343RA (en)	2012-09-26	2015-04-29	Hoffmann La Roche	Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
SG11201502757QA (en)	2012-10-09	2015-05-28	Igenica Biotherapeutics Inc	Anti-c16orf54 antibodies and methods of use thereof
DK3470086T3 (da)	2012-10-12	2020-12-21	Medimmune Ltd	Pyrrolobenzodiazepiner og konjugater deraf
CA2887894C (en)	2012-10-12	2019-10-29	Adc Therapeutics Sarl	Pyrrolobenzodiazepine - anti-psma antibody conjugates
CN105102068B (zh)	2012-10-12	2018-06-01	Adc疗法责任有限公司	吡咯并苯并二氮杂卓-抗体结合物
US10736903B2 (en)	2012-10-12	2020-08-11	Medimmune Limited	Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
WO2014057120A1 (en)	2012-10-12	2014-04-17	Adc Therapeutics Sàrl	Pyrrolobenzodiazepine-antibody conjugates
WO2014059422A1 (en)	2012-10-12	2014-04-17	Exelixis, Inc.	Novel process for making compounds for use in the treatment of cancer
JP6392763B2 (ja)	2012-10-12	2018-09-19	エイディーシー・セラピューティクス・エス・アーＡｄｃＴｈｅｒａｐｅｕｔｉｃｓＳａ	ピロロベンゾジアゼピン−抗体結合体
EP2766048B1 (en)	2012-10-12	2014-12-10	Spirogen Sàrl	Pyrrolobenzodiazepines and conjugates thereof
CA2887899C (en)	2012-10-12	2020-03-31	Adc Therapeutics Sarl	Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
WO2014074785A1 (en)	2012-11-08	2014-05-15	Ludwig Institute For Cancer Research Ltd.	Methods of predicting outcome and treating breast cancer
WO2014078669A1 (en) *	2012-11-15	2014-05-22	Duquesne University Of The Holy Ghost	Carboxylic acid ester prodrug inhibitors of mek
TW201441193A (zh) *	2012-12-06	2014-11-01	Kyowa Hakko Kirin Co Ltd	吡啶酮化合物
US9725703B2 (en)	2012-12-20	2017-08-08	Biomatrica, Inc.	Formulations and methods for stabilizing PCR reagents
AU2013366490B9 (en)	2012-12-21	2018-02-01	Medimmune Limited	Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN105189507A (zh)	2012-12-21	2015-12-23	斯皮罗根有限公司	吡咯并苯并二氮杂卓及其结合物
CA2901114C (en)	2013-02-22	2020-01-07	Stemcentrx, Inc.	Novel antibody conjugates and uses thereof
EP2958592A1 (en)	2013-02-22	2015-12-30	F. Hoffmann-La Roche AG	Methods of treating cancer and preventing drug resistance
US10139415B2 (en)	2013-02-27	2018-11-27	Daiichi Sankyo Company, Limited	Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
CA2901941C (en)	2013-03-13	2020-04-07	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en)	2013-03-13	2016-02-04	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en)	2013-03-13	2017-05-16	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
KR20150127203A (ko)	2013-03-14	2015-11-16	제넨테크, 인크.	Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
EP2968346B1 (en)	2013-03-15	2024-02-07	Cancer Research Technology, LLC	Methods and compositions for gamma-glutamyl cycle modulation
JP6570512B2 (ja)	2013-03-22	2019-09-04	ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙＯｆＨａｗａｉｉ	新規なＳｔａｔ３阻害剤
WO2014197849A2 (en)	2013-06-06	2014-12-11	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
EP3632208A1 (en)	2013-06-13	2020-04-08	Biomatrica, INC.	Cell stabilization
MX2015018038A (es)	2013-07-03	2016-03-16	Hoffmann La Roche	Compuestos de heteroaril-piridona y aza-piridona-amida.
AU2014312215B2 (en)	2013-08-28	2020-02-27	Abbvie Stemcentrx Llc	Site-specific antibody conjugation methods and compositions
US9532987B2 (en) *	2013-09-05	2017-01-03	Genentech, Inc.	Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015159118A2 (en)	2013-09-17	2015-10-22	Obi Pharma, Inc.	Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
EP3054983B1 (en)	2013-10-11	2019-03-20	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en)	2013-10-11	2018-04-24	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en)	2013-10-11	2013-11-27	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en)	2013-10-11	2015-04-16	Spirogen Sàrl	Pyrrolobenzodiazepine-antibody conjugates
MX2016007171A (es)	2013-12-05	2016-09-08	Hoffmann La Roche	Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila.
EP3095462B1 (en)	2014-01-15	2019-08-14	Order-Made Medical Research Inc.	Therapeutic pharmaceutical composition employing anti-slc6a6 antibody
CN104788365B (zh) *	2014-01-16	2018-08-10	上海艾力斯医药科技有限公司	异烟酰胺衍生物、其制备方法及应用
MX2016012007A (es)	2014-03-18	2016-12-05	Hoffmann La Roche	Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso.
GB201406767D0 (en)	2014-04-15	2014-05-28	Cancer Rec Tech Ltd	Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2015166355A2 (en)	2014-04-18	2015-11-05	The Governors Of The University Of Alberta	Targeted therapy to restore radioactive iodine transport in thyroid cancer
MX2016014007A (es)	2014-04-25	2017-01-11	Genentech Inc	Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
WO2015172073A1 (en)	2014-05-08	2015-11-12	Cornell University	Bio-adhesive gels and methods of use
WO2015182734A1 (ja) *	2014-05-30	2015-12-03	協和発酵キリン株式会社	含窒素複素環化合物
JP6661554B2 (ja)	2014-06-10	2020-03-11	バイオマトリカ，インク．	周囲温度における血小板の安定化
AR101210A1 (es)	2014-07-15	2016-11-30	Genentech Inc	Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
US10188746B2 (en)	2014-09-10	2019-01-29	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
RU2017107502A (ru)	2014-09-12	2018-10-12	Дженентек, Инк.	Антитела и конъюгаты, сконструированные введением цистеина
US9518118B2 (en)	2014-09-12	2016-12-13	Genentech, Inc.	Anti-HER2 antibodies and immunoconjugates
GB201416112D0 (en)	2014-09-12	2014-10-29	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
MX2017003472A (es)	2014-09-17	2017-10-31	Genentech Inc	Inmunoconjugados que comprenden anticuerpos anti-her2.
SG11201702079UA (en)	2014-09-17	2017-04-27	Genentech Inc	Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CN106922146B (zh)	2014-10-02	2020-05-26	豪夫迈·罗氏有限公司	用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
TW201625243A (zh)	2014-10-14	2016-07-16	艾克塞里克斯公司	用於治療黑素瘤之藥物組合
WO2016083468A1 (en)	2014-11-25	2016-06-02	Adc Therapeutics Sa	Pyrrolobenzodiazepine-antibody conjugates
WO2016094837A2 (en)	2014-12-11	2016-06-16	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
WO2016095088A1 (en) *	2014-12-15	2016-06-23	Merck Sharp & Dohme Corp.	Erk inhibitors
WO2016095089A1 (en) *	2014-12-15	2016-06-23	Merck Sharp & Dohme Corp.	Erk inhibitors
EP3760623A1 (en)	2014-12-18	2021-01-06	F. Hoffmann-La Roche AG	Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
JP6957035B2 (ja)	2015-04-10	2021-11-02	トーマス・ジェファーソン・ユニバーシティ	対象への移植用の免疫原性拡散チャンバおよびその調製方法
GB201506389D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
GB201506402D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
GB201506411D0 (en)	2015-04-15	2015-05-27	Bergenbio As	Humanized anti-axl antibodies
HRP20241134T1 (hr)	2015-05-30	2024-11-22	F. Hoffmann-La Roche Ag	Metode liječenja her2-pozitivnog prethodno neliječenog metastatskog raka dojke
CN108064246A (zh)	2015-06-15	2018-05-22	基因泰克公司	抗体和免疫结合物
EP3316867B1 (en)	2015-06-30	2021-03-10	Genentech, Inc.	Immediate-release tablets containing a drug and processes for forming the tablets
AR105483A1 (es)	2015-06-30	2017-10-11	Exelixis Inc	Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
US9643980B2 (en)	2015-07-02	2017-05-09	Genentech, Inc.	Benzoxazepin oxazolidinone compounds and methods of use
PL3317284T3 (pl)	2015-07-02	2020-04-30	F. Hoffmann-La Roche Ag	Związki oksazolidynonu benzoksazepiny i sposoby stosowania
WO2017033113A1 (en)	2015-08-21	2017-03-02	Acerta Pharma B.V.	Therapeutic combinations of a mek inhibitor and a btk inhibitor
US10935544B2 (en)	2015-09-04	2021-03-02	Obi Pharma, Inc.	Glycan arrays and method of use
CN108601839B (zh)	2015-11-03	2021-10-26	基因泰克公司	用于治疗癌症的Bcl-2抑制剂和MEK抑制剂组合产品
WO2017087280A1 (en)	2015-11-16	2017-05-26	Genentech, Inc.	Methods of treating her2-positive cancer
KR102702851B1 (ko)	2015-11-19	2024-09-05	제넨테크, 인크.	B-raf 억제제 및 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
CN113588501B (zh)	2015-12-08	2024-12-17	生物马特里卡公司	降低红细胞沉降速率
CN105330643B (zh) *	2015-12-09	2017-12-05	苏州明锐医药科技有限公司	卡比替尼的制备方法
GB201601431D0 (en)	2016-01-26	2016-03-09	Medimmune Ltd	Pyrrolobenzodiazepines
GB201602356D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
EP4529956A2 (en)	2016-02-29	2025-04-02	F. Hoffmann-La Roche AG	Dosage form compositions comprising an inhibitor of bruton s tyrosine kinase
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
US11975002B2 (en)	2016-03-04	2024-05-07	Taiho Pharmaceutical Co., Ltd.	Preparation and composition for treatment of malignant tumors
WO2017172990A1 (en)	2016-03-29	2017-10-05	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
WO2017180581A1 (en)	2016-04-15	2017-10-19	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2017185089A2 (en)	2016-04-22	2017-10-26	Obi Pharma, Inc.	Cancer immunotherapy by immune activation or immune modulation via globo series antigens
GB201607478D0 (en)	2016-04-29	2016-06-15	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
CN106045969B (zh) *	2016-05-27	2019-04-12	湖南欧亚药业有限公司	一种卡比替尼的合成方法
WO2017216280A1 (en)	2016-06-16	2017-12-21	F. Hoffmann-La Roche Ag	TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2017216279A1 (en)	2016-06-16	2017-12-21	F. Hoffmann-La Roche Ag	Heteroaryl estrogen receptor modulators and uses thereof
BR112019001656A2 (pt)	2016-07-27	2019-05-28	Obi Pharma Inc	composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
CN106220607B (zh) *	2016-07-27	2018-09-18	成都百事兴科技实业有限公司	一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法
EP3491026A4 (en)	2016-07-29	2020-07-29	OBI Pharma, Inc.	HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
TW201811369A (zh)	2016-08-12	2018-04-01	美商建南德克公司	Mek抑制劑、pd-1軸抑制劑及vegf抑制劑之組合療法
TW201815419A (zh)	2016-09-29	2018-05-01	美商建南德克公司	Mek抑制劑、 pd-1軸抑制劑及紫杉烷之組合療法
GB201617466D0 (en)	2016-10-14	2016-11-30	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
CN110290800A (zh)	2016-11-21	2019-09-27	台湾浩鼎生技股份有限公司	缀合生物分子、医药组合物及方法
HUE054689T2 (hu)	2017-02-08	2021-09-28	Adc Therapeutics Sa	Pirrolobenzodiazepin-antitest konjugátumok
GB201702031D0 (en)	2017-02-08	2017-03-22	Medlmmune Ltd	Pyrrolobenzodiazepine-antibody conjugates
HRP20211640T1 (hr)	2017-02-08	2022-02-04	Adc Therapeutics Sa	Konjugati pirolobenzodiazepin - protutijelo
CN106866624B (zh) *	2017-02-27	2017-12-26	济宁医学院	一种卡比替尼的化学合成方法
WO2018187478A1 (en)	2017-04-04	2018-10-11	University Of Miami	Biomarkers indicative of prostate cancer and treatment thereof
WO2018192944A1 (en)	2017-04-18	2018-10-25	Medimmune Limited	Pyrrolobenzodiazepine conjugates
KR20190141666A (ko)	2017-04-20	2019-12-24	에이디씨 테라퓨틱스 에스에이	항-axl 항체-약물 접합체로의 병용 요법
WO2018193104A1 (en)	2017-04-20	2018-10-25	Adc Therapeutics Sa	Combination therapy with an anti-cd25 antibody-drug conjugate
WO2018229218A1 (en)	2017-06-14	2018-12-20	Adc Therapeutics Sa	Dosage regimes for the administration of an anti-cd25 adc
WO2018229222A1 (en)	2017-06-14	2018-12-20	Adc Therapeutics Sa	Dosage regimes for the administration of an anti-cd19 adc
SI3668874T1 (sl)	2017-08-18	2022-04-29	Medimmune Limited	Pirolobenzodiazepinski konjugati
TW202428305A (zh)	2017-09-08	2024-07-16	美商建南德克公司	癌症之診斷及治療方法
EP3752200A1 (en)	2018-02-13	2020-12-23	Vib Vzw	Targeting minimal residual disease in cancer with rxr antagonists
GB201803342D0 (en)	2018-03-01	2018-04-18	Medimmune Ltd	Methods
AU2019239404B2 (en)	2018-03-19	2021-12-23	Taiho Pharmaceutical Co., Ltd.	Pharmaceutical composition including sodium alkyl sulfate
WO2019183320A1 (en)	2018-03-21	2019-09-26	Colorado State University Research Foundation	Cancer vaccine compositions and methods of use thereof
EP3757676A4 (en)	2018-03-26	2021-04-07	FUJIFILM Corporation	COMPOSITION OF PHOTOSENSITIVE RESIN, ASSOCIATED PRODUCTION PROCESS, RESERVE FILM, PATTERN FORMATION PROCESS AND PRODUCTION PROCESS OF AN ELECTRONIC DEVICE
GB201806022D0 (en)	2018-04-12	2018-05-30	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
BR112020023846A2 (pt)	2018-05-23	2021-04-13	Adc Therapeutics Sa	Adjuvante molecular
TWI853822B (zh)	2018-06-27	2024-09-01	台灣浩鼎生技股份有限公司	用於糖蛋白工程的糖苷合成酶變體及其使用方法
GB201811364D0 (en)	2018-07-11	2018-08-29	Adc Therapeutics Sa	Combination therapy
BR112021000934A2 (pt)	2018-07-20	2021-04-27	Pierre Fabre Medicament	receptor para vista
JP7590083B2 (ja)	2018-08-31	2024-11-26	アーデーセーセラピューティクスソシエテアノニム	併用療法
JP2022504905A (ja)	2018-10-16	2022-01-13	ノバルティスアーゲー	標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
AU2019383311B2 (en)	2018-11-20	2024-12-05	Nflection Therapeutics, Inc.	Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106303A1 (en)	2018-11-20	2020-05-28	Nflection Therapeutics, Inc.	Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
CA3120352A1 (en) *	2018-11-20	2020-05-28	Nflection Therapeutics, Inc.	Thienyl-aniline compounds for treatment of dermal disorders
WO2020109251A1 (en)	2018-11-29	2020-06-04	Adc Therapeutics Sa	Dosage regime
GB201820725D0 (en)	2018-12-19	2019-01-30	Adc Therapeutics Sarl	Pyrrolobenzodiazepine resistance
EP3899048A1 (en)	2018-12-19	2021-10-27	ADC Therapeutics SA	Pyrrolobenzodiazepine resistance
CA3124330A1 (en)	2018-12-21	2020-06-25	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
MX2021010477A (es)	2019-03-15	2021-10-01	Medimmune Ltd	Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
WO2020187674A1 (en)	2019-03-15	2020-09-24	Sandoz Ag	Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
CA3129665A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
HUE060364T2 (hu)	2019-03-29	2023-02-28	Medimmune Ltd	Vegyületek és konjugátumaik
TWI735210B (zh)	2019-04-26	2021-08-01	中國醫藥大學	Ａｄａｍ９抑制劑作為免疫調節劑之用途
GB201908128D0 (en)	2019-06-07	2019-07-24	Adc Therapeutics Sa	Pyrrolobenzodiazepine-antibody conjugates
KR20220020332A (ko)	2019-06-10	2022-02-18	에이디씨 테라퓨틱스 에스에이	항-cd19 항체 약물 접합체 및 pi3k 억제제 또는 2차 제제를 포함하는 조합 요법
CN114302746A (zh)	2019-06-10	2022-04-08	Adc治疗有限公司	包含抗cd25抗体药物缀合物和另一剂的组合疗法
CA3147397A1 (en)	2019-07-22	2021-01-28	Lupin Limited	Macrocyclic compounds as sting agonists and methods and uses thereof
GB201912059D0 (en)	2019-08-22	2019-10-09	Bergenbio As	Combaination therapy of a patient subgroup
US20240123081A1 (en)	2019-10-25	2024-04-18	Medimmune, Llc	Branched moiety for use in conjugates
JP2023500906A (ja)	2019-11-08	2023-01-11	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
GB201917254D0 (en)	2019-11-27	2020-01-08	Adc Therapeutics Sa	Combination therapy
PL4073025T3 (pl)	2019-12-13	2024-09-16	Inspirna, Inc.	Sole metali i ich zastosowania
CN111170990B (zh) *	2020-01-16	2021-01-05	广州科锐特生物科技有限公司	一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
TW202140076A (zh)	2020-01-22	2021-11-01	英商梅迪繆思有限公司	化合物及其軛合物
MX2022009052A (es)	2020-01-22	2022-08-15	Medimmune Ltd	Compuestos y conjugados de estos.
GB202004189D0 (en)	2020-03-23	2020-05-06	Bergenbio As	Combination therapy
EP4134081A4 (en)	2020-04-10	2024-05-01	Taiho Pharmaceutical Co., Ltd.	CANCER THERAPY USING 3,5-DISUBSTITUTED ALCYNYL BENZENE COMPOUND AND MEK INHIBITOR
AU2021255711A1 (en)	2020-04-16	2022-10-27	Regeneron Pharmaceuticals, Inc.	Diels-alder conjugation methods
GB202006072D0 (en)	2020-04-24	2020-06-10	Bergenbio Asa	Method of selecting patients for treatment with cmbination therapy
EP3915576A1 (en)	2020-05-28	2021-12-01	Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron	Chimeric antigen receptors specific for p95her2 and uses thereof
EP3939999A1 (en)	2020-07-14	2022-01-19	Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
GB202011993D0 (en)	2020-07-31	2020-09-16	Adc Therapeutics Sa	ANTI-IL 13Ra2 antibodies
GB202012161D0 (en)	2020-08-05	2020-09-16	Adc Therapeutics Sa	Combination therapy
JP2023537626A (ja)	2020-08-14	2023-09-04	グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド	Ｂｔｋ及びその変異体の阻害剤を含む剤形組成物
GB202015226D0 (en)	2020-09-25	2020-11-11	Adc Therapeutics S A	Pyrrol obenzodiazepine-antibody conugates and uses thereof
GB202015916D0 (en)	2020-10-07	2020-11-18	Adc Therapeutics Sa	Combination therapy
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
JP2024509269A (ja)	2021-03-09	2024-02-29	ジェネンテック，インコーポレイテッド	脳がんの治療における使用のためのベルバラフェニブ
JP2024511373A (ja)	2021-03-18	2024-03-13	ノバルティスアーゲー	がんのためのバイオマーカーおよびその使用
KR20230165795A (ko)	2021-04-06	2023-12-05	제넨테크, 인크.	벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법
GB202107713D0 (en)	2021-05-28	2021-07-14	Medimmune Ltd	Combination therapy
GB202107706D0 (en)	2021-05-28	2021-07-14	Adc Therapeutics S A	Combination therapy
GB202107709D0 (en)	2021-05-28	2021-07-14	Adc Therapeutics S A	Combination therapy
KR102699226B1 (ko)	2021-06-09	2024-08-27	에프. 호프만-라 로슈 아게	암 치료를 위한 병용요법
MX2023015264A (es)	2021-06-29	2024-01-19	Adc Therapeutics Sa	Terapia de combinaicon con conjugados de anticuerpo-farmaco.
WO2023057545A1 (en)	2021-10-06	2023-04-13	Microquin Ltd.	Substituted chalcones
IL312171A (en)	2021-11-04	2024-06-01	Hoffmann La Roche	Innovative use of the quinazolinone compound for cancer treatment
AU2022409717A1 (en)	2021-12-16	2024-05-30	Pags Co., Ltd.	Cell penetrating polypeptides (cpps) and their use in human therapy
TW202342018A (zh)	2022-03-04	2023-11-01	美商奇奈特生物製藥公司	Mek激酶抑制劑
MX2024011234A (es) *	2022-03-17	2024-09-23	Springworks Therapeutics Inc	Compuestos fluorados de fenilamino y composiciones farmaceuticas.
EP4253418A1 (en)	2022-03-29	2023-10-04	Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron	Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
GB202209285D0 (en)	2022-06-24	2022-08-10	Bergenbio Asa	Dosage regimen for AXL inhibitor
WO2024033381A1 (en)	2022-08-10	2024-02-15	Vib Vzw	Inhibition of tcf4/itf2 in the treatment of cancer
WO2024105144A1 (en)	2022-11-18	2024-05-23	F. Hoffmann-La Roche Ag	Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
EP4406973A1 (en)	2023-01-27	2024-07-31	Fundació Privada Institut de Recerca de la SIDA-Caixa	Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
WO2025029650A1 (en)	2023-07-28	2025-02-06	Li Xiyan	Nutritionally modified diets comprising aminoacids for use in treating a disease
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4510139A (en) *	1984-01-06	1985-04-09	Sterling Drug Inc.	Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en)	1987-10-27	1992-10-13	Warner-Lambert Company	Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
JPH03192592A (ja)	1989-12-21	1991-08-22	Matsushita Electric Ind Co Ltd	磁気テープ記録再生装置
US6048885A (en) *	1994-04-01	2000-04-11	Shionogi & Co., Ltd.	Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en)	1995-10-05	1997-04-28	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en)	1997-02-28	1998-09-03	Warner Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
ES2274572T3 (es)	1997-07-01	2007-05-16	Warner-Lambert Company Llc	Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
CA2290506C (en)	1997-07-01	2005-12-27	Warner-Lambert Company	4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6974878B2 (en) *	2001-03-21	2005-12-13	Symyx Technologies, Inc.	Catalyst ligands, catalytic metal complexes and processes using same
KR20010101203A (ko)	1998-12-15	2001-11-14	로즈 암스트롱, 크리스틴 에이. 트러트웨인	Ｍｅｋ 저해제의 이식 조직 거부를 예방하기 위한 용도
EP1143957A3 (en)	1998-12-16	2002-02-27	Warner-Lambert Company	Treatment of arthritis with mek inhibitors
CA2352326A1 (en)	1998-12-22	2000-06-29	Warner-Lambert Company	Combination chemotherapy
KR20000047461A (ko)	1998-12-29	2000-07-25	성재갑	트롬빈 억제제
IL144103A0 (en)	1999-01-07	2002-05-23	Warner Lambert Co	Antiviral method using mek inhibitors
EP1140062B1 (en)	1999-01-07	2005-04-06	Warner-Lambert Company LLC	Treatment of asthma with mek inhibitors
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
AU2483400A (en) *	1999-01-13	2000-08-01	Warner-Lambert Company	4'heteroaryl diarylamines
JP2002534515A (ja)	1999-01-13	2002-10-15	ワーナー−ランバート・カンパニー	１−複素環置換されたジアリールアミン
OA11746A (en) *	1999-01-13	2005-05-13	Warner Lambert Co	Benzoheterocycles and their use as MEK inhibitors.
ATE309205T1 (de)	1999-01-13	2005-11-15	Warner Lambert Co	Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
AU5786000A (en)	1999-07-16	2001-02-05	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
TR200200204T2 (tr)	1999-07-16	2002-11-21	Warner-Lambert Company	MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
CA2377092A1 (en)	1999-07-16	2001-01-25	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
WO2001005393A2 (en)	1999-07-16	2001-01-25	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
BR0014076A (pt)	1999-09-17	2002-10-15	Millennium Pharm Inc	Benzamidas e inibidores correlatos do fator xa
AU2001247372A1 (en)	2000-03-15	2001-09-24	Warner Lambert Company	5-amide substituted diarylamines as mex inhibitors
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
KR100773621B1 (ko)	2000-07-19	2007-11-05	워너-램버트 캄파니 엘엘씨	4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르
NZ518726A (en)	2001-05-09	2004-06-25	Warner Lambert Co	Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10141266A1 (de) *	2001-08-21	2003-03-06	Syntec Ges Fuer Chemie Und Tec	Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
JP2003192592A (ja)	2001-10-17	2003-07-09	Sankyo Co Ltd	医薬組成物
HUP0401967A2 (hu)	2001-10-31	2005-01-28	Pfizer Products Inc.	Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására
JP2005515253A (ja)	2002-01-23	2005-05-26	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
DOP2003000556A (es)	2002-01-23	2003-10-31	Warner Lambert Co	Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
CN1652792A (zh)	2002-03-13	2005-08-10	阵列生物制药公司	作为mek抑制剂的n3烷基化苯并咪唑衍生物
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
PT2130537E (pt) *	2002-03-13	2012-12-20	Array Biopharma Inc	Derivados de benzimidazole n3 alquilado como inibidores de mek
EP1515727A4 (en)	2002-06-11	2009-04-08	Merck & Co Inc	INHIBITORS OF P38 KINASE (HALO-BENZO CARBONYL) HETEROBICYCLIC
GB0214268D0 (en) *	2002-06-20	2002-07-31	Celltech R&D Ltd	Chemical compounds
US20050004186A1 (en)	2002-12-20	2005-01-06	Pfizer Inc	MEK inhibiting compounds
PL214032B1 (pl) *	2003-03-03	2013-06-28	Array Biopharma	Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38
TW200505834A (en)	2003-03-18	2005-02-16	Sankyo Co	Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja)	2003-03-18	2005-06-23	Sankyo Co Ltd	スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
WO2004113347A1 (en) *	2003-06-20	2004-12-29	Celltech R & D Limited	Thienopyridone derivatives as kinase inhibitors
WO2005000818A1 (en)	2003-06-27	2005-01-06	Warner-Lambert Company Llc	5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007616A1 (en) *	2003-07-23	2005-01-27	Warner-Lambert Company Llc	Diphenylamino ketone derivatives as mek inhibitors
US20050049276A1 (en) *	2003-07-23	2005-03-03	Warner-Lambert Company, Llc	Imidazopyridines and triazolopyridines
EP1651214B1 (en) *	2003-07-24	2009-09-16	Warner-Lambert Company LLC	Benzimidazole derivatives as mek inhibitors
US7538120B2 (en) *	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
US7144907B2 (en) *	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) *	2003-09-19	2011-12-27	Chugai Seiyaku Kabushiki Kaisha	4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
PL1689233T3 (pl) *	2003-11-19	2012-11-30	Array Biopharma Inc	Bicykliczne inhibitory MEK
US7517994B2 (en) *	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
CN100509808C (zh) *	2003-12-08	2009-07-08	霍夫曼-拉罗奇有限公司	新型噻唑衍生物
MY144232A (en)	2004-07-26	2011-08-15	Chugai Pharmaceutical Co Ltd	5-substituted-2-phenylamino benzamides as mek inhibitors
PE20060572A1 (es)	2004-07-27	2006-06-27	Novartis Ag	Compuestos de benzoimidazolona como inhibidores de hsp90
AU2005298932B2 (en)	2004-10-20	2012-03-22	Merck Serono Sa	3-arylamino pyridine derivatives
WO2006061712A2 (en)	2004-12-10	2006-06-15	Pfizer Inc.	Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
NO347091B1 (no) *	2005-10-07	2023-05-15	Exelixis Inc	Forbindelser og farmasøytiske sammensetninger til behandling av proliferative sykdommer
EP2056829B9 (en) *	2006-08-16	2012-09-26	Exelixis, Inc.	Using pi3k and mek modulators in treatments of cancer

2006
- 2006-10-05 NO NO20200035A patent/NO347091B1/no unknown
- 2006-10-05 EA EA201400111A patent/EA025871B9/ru not_active IP Right Cessation
- 2006-10-05 WO PCT/US2006/039126 patent/WO2007044515A1/en active Application Filing
- 2006-10-05 GE GEAP200610685A patent/GEP20125456B/en unknown
- 2006-10-05 CA CA2622755A patent/CA2622755C/en active Active
- 2006-10-05 EA EA200801041A patent/EA019983B1/ru active Protection Beyond IP Right Term
- 2006-10-05 EP EP06825554A patent/EP1934174B1/en active Active
- 2006-10-05 ES ES06825554T patent/ES2365070T3/es active Active
- 2006-10-05 CN CN2006800449476A patent/CN101365676B/zh active Active
- 2006-10-05 RS RS20110277A patent/RS51782B/en unknown
- 2006-10-05 AU AU2006302415A patent/AU2006302415B2/en active Active
- 2006-10-05 DE DE602006021205T patent/DE602006021205D1/de active Active
- 2006-10-05 CN CN201910851634.0A patent/CN110668988A/zh active Pending
- 2006-10-05 CA CA2927656A patent/CA2927656C/en active Active
- 2006-10-05 JP JP2008534706A patent/JP5129143B2/ja active Active
- 2006-10-05 DK DK06825554.6T patent/DK1934174T3/da active
- 2006-10-05 CN CN201510197206.2A patent/CN104892582B/zh active Active
- 2006-10-05 CN CN201810489110.7A patent/CN109053523B/zh active Active
- 2006-10-05 AT AT06825554T patent/ATE504565T1/de active
- 2006-10-05 KR KR1020137010590A patent/KR20130058072A/ko not_active Ceased
- 2006-10-05 MY MYPI20080982A patent/MY162174A/en unknown
- 2006-10-05 PT PT06825554T patent/PT1934174E/pt unknown
- 2006-10-05 BR BRPI0617165A patent/BRPI0617165B1/pt active IP Right Grant
- 2006-10-05 SI SI200631043T patent/SI1934174T1/sl unknown
- 2006-10-05 NZ NZ567140A patent/NZ567140A/en unknown
- 2006-10-05 CN CN201310366896.0A patent/CN103524392B/zh active Active
- 2006-10-05 CA CA3052368A patent/CA3052368A1/en not_active Abandoned
- 2006-10-05 EA EA201691142A patent/EA032466B1/ru unknown
- 2006-10-05 PL PL06825554T patent/PL1934174T3/pl unknown
- 2006-10-05 US US11/995,928 patent/US7803839B2/en active Active
2008
- 2008-03-03 IL IL189900A patent/IL189900A/en active Protection Beyond IP Right Term
- 2008-03-05 ZA ZA200802075A patent/ZA200802075B/xx unknown
- 2008-04-04 KR KR1020087008141A patent/KR101341792B1/ko active Active
- 2008-05-05 NO NO20082088A patent/NO344876B1/no active Protection Beyond IP Right Term
- 2008-11-25 HK HK08112886.4A patent/HK1119698A1/xx unknown
2010
- 2010-05-05 US US12/774,544 patent/US7915250B2/en active Active
2011
- 2011-03-15 US US13/048,832 patent/US8362002B2/en active Active
- 2011-07-04 CY CY20111100646T patent/CY1111670T1/el unknown
- 2011-07-05 HR HR20110498T patent/HRP20110498T1/hr unknown
2012
- 2012-09-05 JP JP2012195223A patent/JP5678019B2/ja active Active
2013
- 2013-06-27 US US13/929,062 patent/US20140275527A1/en not_active Abandoned
- 2013-10-30 IL IL229136A patent/IL229136A/en active IP Right Grant
2014
- 2014-03-13 JP JP2014049674A patent/JP5856211B2/ja active Active
- 2014-06-10 IL IL233053A patent/IL233053A0/en unknown
2015
- 2015-02-05 US US14/615,079 patent/US20170166523A9/en not_active Abandoned
- 2015-09-24 JP JP2015186392A patent/JP2015232045A/ja active Pending
2016
- 2016-03-07 HK HK16102537.8A patent/HK1214595A1/zh unknown
- 2016-05-13 HU HUS1600021C patent/HUS1600021I1/hu unknown
- 2016-05-17 LT LTPA2016016C patent/LTC1934174I2/lt unknown
- 2016-05-18 NL NL300809C patent/NL300809I2/nl unknown
- 2016-05-18 CY CY2016015C patent/CY2016015I1/el unknown
- 2016-05-19 FR FR16C0021C patent/FR16C0021I2/fr active Active
- 2016-05-19 LU LU93078C patent/LU93078I2/fr unknown
2017
- 2017-03-02 JP JP2017038954A patent/JP2017101071A/ja active Pending
- 2017-03-15 IL IL251185A patent/IL251185A0/en unknown
2018
- 2018-01-17 JP JP2018005721A patent/JP2018058907A/ja not_active Withdrawn
- 2018-04-13 US US15/952,923 patent/US20190144382A1/en not_active Abandoned
- 2018-06-19 IL IL260127A patent/IL260127B/en unknown
2019
- 2019-02-25 JP JP2019031850A patent/JP2019089841A/ja not_active Withdrawn
- 2019-10-09 US US16/597,607 patent/US20200031770A1/en not_active Abandoned
2020
- 2020-04-20 US US16/853,043 patent/US11597699B2/en active Active
- 2020-08-21 JP JP2020139894A patent/JP2020189882A/ja active Pending
- 2020-09-04 NO NO2020031C patent/NO2020031I1/no unknown
2023
- 2023-05-11 NO NO2023022C patent/NO2023022I1/no unknown
2024
- 2024-05-23 US US18/672,226 patent/US20250100966A1/en active Pending

Also Published As

Publication number	Publication date
AU2006302415A1 (en)	2007-04-19
IL189900A (en)	2014-06-30
CA3052368A1 (en)	2007-04-19
IL229136A0 (en)	2013-12-31
US20110263558A1 (en)	2011-10-27
JP2014111659A (ja)	2014-06-19
LU93078I2 (fr)	2016-07-19
US8362002B2 (en)	2013-01-29
JP2019089841A (ja)	2019-06-13
NO347091B1 (no)	2023-05-15
JP5856211B2 (ja)	2016-02-09
CN101365676B (zh)	2013-09-11
JP2018058907A (ja)	2018-04-12
CA2927656C (en)	2019-09-24
US20250100966A1 (en)	2025-03-27
JP5678019B2 (ja)	2015-02-25
BRPI0617165B1 (pt)	2023-10-03
DE602006021205D1 (de)	2011-05-19
CY2016015I2 (el)	2016-10-05
RS51782B (en)	2011-12-31
EA032466B1 (ru)	2019-05-31
FR16C0021I2 (fr)	2017-04-14
CN103524392A (zh)	2014-01-22
JP2020189882A (ja)	2020-11-26
CA2927656A1 (en)	2007-04-19
CN103524392B (zh)	2018-06-01
FR16C0021I1 (no)	2016-06-24
NZ567140A (en)	2011-09-30
KR20130058072A (ko)	2013-06-03
EA025871B1 (ru)	2017-02-28
HK1214595A1 (zh)	2016-07-29
NO2020031I1 (no)	2020-09-04
NO20200035A1 (no)	2008-06-17
BRPI0617165A2 (pt)	2015-01-06
US20100249096A1 (en)	2010-09-30
CN109053523B (zh)	2022-03-25
EP1934174B1 (en)	2011-04-06
JP2013014601A (ja)	2013-01-24
IL260127A (en)	2018-07-31
US20190144382A1 (en)	2019-05-16
NO344876B1 (no)	2020-06-08
JP2017101071A (ja)	2017-06-08
ATE504565T1 (de)	2011-04-15
KR20080050601A (ko)	2008-06-09
CN104892582A (zh)	2015-09-09
NL300809I2 (no)	2016-10-19
SI1934174T1 (sl)	2011-08-31
US11597699B2 (en)	2023-03-07
PT1934174E (pt)	2011-07-14
CN101365676A (zh)	2009-02-11
US7915250B2 (en)	2011-03-29
PL1934174T3 (pl)	2011-09-30
EA201691142A1 (ru)	2017-02-28
US20200031770A1 (en)	2020-01-30
LTC1934174I2 (lt)	2018-01-10
GEP20125456B (en)	2012-03-26
IL233053A0 (en)	2014-07-31
IL251185A0 (en)	2017-05-29
HUS1600021I1 (hu)	2016-06-28
CY1111670T1 (el)	2015-10-07
CA2622755A1 (en)	2007-04-19
CA2622755C (en)	2017-01-31
JP2009511490A (ja)	2009-03-19
EA200801041A1 (ru)	2009-02-27
HRP20110498T1 (hr)	2011-08-31
WO2007044515A1 (en)	2007-04-19
MY162174A (en)	2017-05-31
US7803839B2 (en)	2010-09-28
CN104892582B (zh)	2019-09-27
EA025871B9 (ru)	2017-08-31
EA201400111A1 (ru)	2014-09-30
EP1934174A1 (en)	2008-06-25
NO20082088L (no)	2008-06-17
CN109053523A (zh)	2018-12-21
LTPA2016016I1 (lt)	2016-06-10
IL229136A (en)	2015-11-30
US20150141399A1 (en)	2015-05-21
EA019983B1 (ru)	2014-07-30
AU2006302415B2 (en)	2012-09-13
IL189900A0 (en)	2008-08-07
ZA200802075B (en)	2009-08-26
KR101341792B1 (ko)	2013-12-23
IL260127B (en)	2022-04-01
JP2015232045A (ja)	2015-12-24
DK1934174T3 (da)	2011-08-01
US20200283383A1 (en)	2020-09-10
JP5129143B2 (ja)	2013-01-23
ES2365070T3 (es)	2011-09-21
US20090156576A1 (en)	2009-06-18
CY2016015I1 (el)	2016-10-05
US20140275527A1 (en)	2014-09-18
HK1119698A1 (en)	2009-03-13
CN110668988A (zh)	2020-01-10
US20170166523A9 (en)	2017-06-15

Publication	Publication Date	Title
NO2023022I1 (no)	2023-05-11	cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
UA109417C2 (uk)	2015-08-25	ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
NO20081554L (no)	2008-06-02	Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
HK1120506A1 (en)	2009-04-03	Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
TW200613243A (en)	2006-05-01	Novel compounds
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200639156A (en)	2006-11-16	New compounds
EA201001196A1 (ru)	2011-02-28	Соединения 4-пиридинона и их применение для лечения рака
UA96742C2 (en)	2011-12-12	Mek inhibitors and use thereof
EA201990219A3 (ru)	2019-10-31	Ингибиторы mek и способы их применения
UA95250C2 (ru)	2011-07-25	Пиридинаминосульфонил-замещенные бензамиды как ингибиторы цитохром р450 3а4 (cyp4503a4)